UNSPSC 51453300: Anthelmintic sulfides

Anthelmintic drugs made from chemical groups containing the covalent sulfur bonds -S-.

UNSPSC 51453300 Anthelmintic sulfides is a Class code that in recent state and local procurement activity encompasses pharmaceutical products and medical supplies far broader than the code's abstract name suggests—specifically naloxone, drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and emergency medical supplies for fire rescue operations. State and local issuing bodies soliciting under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and cooperative purchasing alliances serving multi-state government networks (Minnesota Multistate Cooperative Purchasing Alliance). The work ranges from direct procurement of specific pharmaceutical units to establishing blanket contracts with authorized wholesalers for ongoing supply distribution to government facilities.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, the City of Tampa's IFB 26P00145 (posted March 25, 2026; due March 13, 2026) for 169 line items of medical and first aid supplies to the Fire Department Rescue Division with an estimated contract amount of $700,000 and a 5 percent bid discount for certified Small Local Business Enterprises, the Minnesota Department of Administration's RFP S1070000015802 through MMCAP (posted January 20, 2026; due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon with proposals evaluated 75 percent on price competitiveness, and the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026; due April 3, 2026) gathering vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program. The Tampa procurement emphasizes SLBE participation and local outreach; the MMCAP RFP requires relationships with specific authorized wholesalers and cGMP compliance with performance penalties for non-compliance.